The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Inclusion Criteria: * ≥ 18 years old at screening visit * Diagnosed with RA according to 1987 or 2010 criteria of the American College of Rheumatology * At the time of the pre-baseline visit, patient has a CDAI score of \>10 * Currently taking one or more non-biologic or biologic DMARD at screening and for at least the 3 months prior to screening * Visit at time of screening scheduled as part of routine care * Subject and/or physician willing to consider treatment change at screening * No expectation of imminent treatment change at screening or baseline visit Exclusion Criteria: * Currently taking an anti-IL-6R drug (tocilizumab, sarilumab) * Any contraindication, administrative barrier, or financial limitation (e.g. no insurance coverage) that makes it impossible for subject to receive at least one new biologic or JAKi therapy for RA * Active infection * History of malignancy within the past 5 years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ that has been treated or excised in a curative procedure * Current enrollment in another clinical trial * Any condition or circumstance that makes it likely the patient will not be able to complete the trial